Forte Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Forte Biosciences, Inc. (FBRX) on March 31, 2022. The company is a Delaware corporation with principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Capital Market. The filing reports the entry into a material definitive agreement regarding the sale of company securities.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the authorization to sell up to $25,000,000 of common stock under a new sales agreement. A prospectus supplement has been filed covering an initial tranche of up to $7,000,000.
Material Changes
On March 31, 2022, the Company entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. This agreement allows the Company to offer and sell its common stock from time to time through Ladenburg as agent. The Company is not obligated to sell any shares under this agreement.
Outlook, Risks, and Management Commentary
- Use of Proceeds: The Company intends to use net proceeds from the offering, if any, for general corporate purposes, including funding existing and potential new clinical programs.
- Commission: The Company agreed to pay Ladenburg a commission equal to 3.0% of the gross proceeds from sales of shares pursuant to the agreement.
- Termination: The agreement may be terminated at any time by either party or upon the sale of all authorized shares.
- Risk Disclosure: The filing notes that the agreement is not intended as a document for investors to obtain factual information about the Company's current state of affairs and directs investors to other SEC filings for such data.
Investor Verification Checklist
- Verify the actual volume and pricing of shares sold under the agreement in subsequent filings.
- Review the Company's most recent 10-K or 10-Q for current cash position and burn rate to assess the necessity of this capital raise.
- Confirm the status of the Company's clinical programs mentioned as a use of proceeds.
- Monitor for any termination of the sales agreement by either party.